IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 604-704 M#

C# 1644

BOLT et al

Serial No. 10/743,423

Examiner: Marianne Nmn Dibrino

光TC/A.U.

Date: December 5, 2005 Filed: December 23, 2003

HUMANIZED ANTI-CD3 SPECIFIC ANTIBODIES (AS AMENDED) Title:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE/AMENDMENT/LETTER

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ Correspondence Address Indication Form Attached.

Fees are attached as calculated below:

Total effective claims after amendment 27 minus highest number previously paid for 427 (at least 20) = 0 x \$50.00 \$0.00 (1202)/	/\$0.00 (2202)	\$	0.00
Independent claims after amendment previously paid for 3 (at least 3) = 0 x \$200.00 \$0.00 (1201)	/\$0.00 (2201)	\$	0.00
If proper multiple dependent claims now added for first time, (ignore improper); add			
\$360.00 (1051)/\$1	80.00 (2051)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) One Month Extension \$120.00 (1251)/\$60 Two Month Extensions \$450.00 (1252)/\$220 Three Month Extensions \$1020.00 (1253/\$510) Four Month Extensions \$1590.00 (1254/\$7	5.00 (2252) 0.00 (2253)	\$	0.00
Terminal disclaimer enclosed, add \$130.00 (1814)/ \$6	65.00 (2814)	\$	0.00
☐ Applicant claims "small entity" status. ☐ Statement filed herewith	,	,	
Rule 56 Information Disclosure Statement Filing Fee \$180	0.00 (1806)	\$	0.00
Assignment Recording Fee \$4	0.00 (8021)	\$	0.00
Other:		\$	0.00
TOTAL FEE	ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

901 North Glebe Road, 11th Floor Arlington, Virginia 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

LCM:Ifm

NIXON & VANDERHYE P.C.

By Atty: Leonard C. Mitchard, Reg. No. 29,009

Signature:

1019891



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BOLT et al

Atty. Ref.: 604-704; Confirmation No. 9858

Appl. No. 10/743,423

TC/A.U. 1644

Filed: December 23, 2003

Examiner: Marianne Nmn Dibrino

For: HUMANIZED ANTI-CD3 SPECIFIC ANTIBODIES (AS AMENDED)

December 5, 2005

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Official Action mailed November 3, 2005, and the requirement for restriction presented in it, applicants elect the subject matter of Group III, that is claim 27, directed to a method of treatment of a patient requiring immunosuppression, said method comprising administering an aglycosylated IgG anti-CD3 antibody to said patient.

An examination on the merits is awaited.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Leonard C. Mitchau Reg. No. 29.009

LCM:Ifm 901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100